Focused on developing novel compounds to treat cancer

At Apexian, our mission is simple:
Find safe and effective therapies that will improve the lives of cancer patients.

Apexian is a biotechnology company focused on developing novel compounds to treat cancer. Our lead drug candidate – APX3330 – targets the APE1/Ref-1 redox protein, a molecule found in many cancers, including tumors of the colon, lung, breast, pancreas and others. Our experienced team of research scientists and clinical specialists will commence studies of APX3330 for the treatment of cancer in 2017.

Our scientific founder and Chief Scientific Officer, Dr. Mark R. Kelley, is the world’s leading expert in APE1/Ref-1 protein biology.

markkelley2017_280_186He is also the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor in the Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology, Indiana University School of Medicine. Dr. Kelley is the Associate Director of the Herman B Wells Center for Pediatric Research and for Basic Science Research at the IU Simon Cancer Center.

+ read more about the Apexian team

Our science is unique and represents first-in-class therapeutic potential.

testtube280Inhibition of the APE1/Ref-1 redox protein affects signaling pathways critical to cancer cell survival, and APX3330 has shown dramatic anti-cancer effect in numerous pre-clinical models of human cancers. Our human studies will evaluate the safety and efficacy of APX3330 in patients with a variety of cancers that express the APE1/Ref-1 protein.

+ read more about the R&D at Apexian

Our focus is on developing drugs to fight the most deadly cancers, most of which overexpress APE1


Our clinical development plan is focused on testing APX3330 against advanced cancers that express the APE1/Ref-1 protein. These advanced cancers constitute areas of high unmet medical need, and include deadly forms of cancer involving the lung, colon, breast, pancreas, brain and others. The APE1/Ref-1 protein is also expressed in certain pediatric and hematologic cancers, underscoring the importance of this molecular target.

+ Read more about APE1/Ref-1 and Apexian cancer research


Apexian Pharmaceuticals research and clinical testing featured on Inside Indiana Business

Pancreatic cancer is the fourth leading cause of cancer-related death in the U.S. Barbara Lewis talks with the scientific founder of Apexian Pharmaceuticals about a drug that could make a difference.
Watch here –  from December 2


Mark R. Kelley, PhD and Indiana University cancer researchers have been awarded $2.9 million to study the debilitating side effects caused by chemotherapy that affect a significant number of cancer patients. Kelley received the grant  from the National Cancer Institute to study chemotherapy-induced peripheral neuropathy (CIPN).

Although cancer treatments are becoming more effective and people are consequently surviving cancer in increasing rates, many patients report neuropathy – a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness. As many as 30 percent to 60 percent of cancer patients say they experience neuropathy. Neuropathy can become severe enough for some patients that their treatment needs to be reduced or stopped. The effects can also linger well beyond the course of the treatment.
+ Read more on this story
+ Read all Apexian News